Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents

Histone deacetylases (HDACs) inhibitors are active in T-cell lymphoma and are undergoing pre-clinical and clinical testing in other neoplasms. Entinostat is an orally bioavailable class I HDAC inhibitor with a long half-life, which is under evaluation in haematological and solid tumour malignancies....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Principais autores: Frys, Sarah, Simons, Zachary, Hu, Qiang, Barth, Matthew J., Gu, Juan J., Mavis, Cory, Skitzki, Joseph, Song, Liu, Czuczman, Myron S., Hernandez-Ilizaliturri, Francisco J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5802357/
https://ncbi.nlm.nih.gov/pubmed/25712263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13318
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados